Long-term disease control in Psoriasis: announcing a new project
A new educational project in psoriasis
Medthority.com is pleased to announce a unique and interactive educational programme launching with a new symposium, focusing on long-term disease control in psoriasis, and taking place at one of 2019’s leading European dermatology congresses.
Featuring an expert faculty, who will consider the use of biologics in moderate to severe psoriasis, the educational symposium will take place at the 28th European Academy of Dermatology and Venerology (EADV) Congress in Madrid on 10 October 2019. Commenting on the project, Commercial Director Jonathan McDonald said:
This is a really exciting project which will provide a novel learning for practicing dermatologists, but also family medicine doctors. We're delighted to be running a symposium with Almirall S.A and looking forward to sharing the highlights from the symposium exclusively on Medthority.com.
You can register your interest to attend the symposium using this form.
The highlights from the symposium will be exclusively available on Medthority.com as part of the Psoriasis Academy, which is due to launch in parallel with EADV.
Addressing the unmet needs in moderate to severe psoriasis, the Psoriasis Academy will draw on the experience of practicing dermatologists, GPs and allied healthcare professionals.
The Psoriasis Academy will serve as a central repository for those specialists who are already aware of the current market but want to remain up to date on the latest treatment research and development. As well as providing an easily accessible source of information, the Psoriasis Academy will provide a platform for HCPs to share their clinical experience.
It will feature recorded highlights from the EADV symposium, along with case studies and interviews with leading experts.
The faculty, including Professor Diamant Thaçi, Professor Luis Puig, and Professor Stefano Piaserico, will consider the case studies in a wider disease awareness context. Placed within a firm scientific background, the final learning resource will be a unique portfolio of go-to examples for quick reference.
If you are not attending - don't worry! Medthority.com will be hosting the recorded highlights post-event.
About the project
Delivered through an arms-length educational grant with Almirall S.A, this project will see the development of a series of independent learning resources, delivered across multiple channels to influence unmet needs in moderate to severe psoriasis. Published to Medthority.com, the website for healthcare professionals, it aims to bring together healthcare professionals from around the world.
About the symposium
BIOLOGICS IN MODERATE TO SEVERE PSORIASIS: DISCOVER THE ROAD TO LONG-TERM CONTROL (Accredited for 1 ECMEC CME point)
Thursday 10 October 2019, 17.00–18.30, room N105-106 IFEMA Feria de Madrid, Madrid, Spain
- Professor Diamant Thaçi
- Professor Luis Puig
- Professor Stefano Piaserico
- Mind the gap: benefits of modern biologic treatment
- En route to long-term control?
- Targeting safety in treatment decisions: Navigating the options - which way will you go?
When it comes to psoriasis, a knowledgeable healthcare professional is highly valued by patients (Pariser et al., 2016). With this in mind, we created The Psoriasis Academy, an online hub featuring succinct and easily accessible information for all healthcare professionals who want to know more about psoriasis and keep up to date with the latest developments.
Related news and insights
AbbVie announced new 52-week data from an open-label, single-arm study demonstrating improved plaque psoriasis signs and symptoms among a difficult-to-treat patient population who received Skyrizi (risankizumab), an IL-23 inhibitor.
Dermavant Sciences, announced positive results from ADORING 2, one of two double-blind, randomized, vehicle-controlled Phase III studies to evaluate the efficacy and safety of topical Vtama (tapinarof) cream, 1% in pediatric subjects down to 2 years old and adult subjects with atopic dermatitis (AD).
Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Sotyktu (deucravacitinib) for the treatment of adults with moderate-to-severe plaque psoriasis. The CHMP recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union (EU).